Serum miR-632 is a potential marker for the diagnosis and prognosis in laryngeal squamous cell carcinoma

Abstract

<b>Background:</b> It has been demonstrated that miRNAs play critical roles in the tumorigenesis and progression of various tumors.<b>Objective:</b> The purpose of this research was to determine the serum miR-632 levels in patients with laryngeal squamous cell carcinoma (LSCC) and to investigate its diagnostic and prognostic value.<b>Materials and methods:</b> We detected serum miR-632 levels in 162 LSCC patients and 42 healthy volunteers. The ROC curve was carried out to determine diagnostic accuracy.<b>Results:</b> We observed that serum miR-632 levels were upregulated in LSCC patients compared with healthy volunteers (<i>p</i> < .01). Subsequent results from ROC indicated that high sensitivity and specificity of serum miR-632 for diagnosing LSCC (area under the curve 0.8828). In addition, it was found that high expressions of serum miR-632 were significantly associated with advanced N stage (<i>p</i> = .020), histological grade (<i>p</i> = .001), and TNM stage (<i>p</i> = .014). Furthermore, patients with higher serum miR-632 expression had a shorter OS and DFS time than those with lower serum miR-632 levels.<b>Conclusion:</b> Our data revealed that serum miR-632 may be a potential noninvasive biomarker which may become a potential diagnostic and prognostic biomarker for LSCC patients.